Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Astria Therapeutics ( (ATXS) ) has issued an announcement.
Astria Therapeutics, Inc. has amended its 2022 Inducement Stock Incentive Plan to increase the shares of common stock reserved for issuance from 1,700,000 to 2,800,000. This amendment, made without stockholder approval, aims to attract new talent by offering stock awards to individuals not previously employed by the company, potentially strengthening its workforce and aligning employee interests with those of shareholders.
More about Astria Therapeutics
Astria Therapeutics, Inc. operates in the biotechnology industry, focusing on developing therapies to address unmet medical needs.
YTD Price Performance: 21.88%
Average Trading Volume: 339,206
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $528.2M
For a thorough assessment of ATXS stock, go to TipRanks’ Stock Analysis page.
